The advent of anti–vascular endothelial growth factor (anti-VEGF) therapy has represented a paradigm shift in the treatment of neovascular age-related macular degeneration (nAMD). However, anti-VEGF injections require frequent office visits for administration to maintain visual acuity gains, placing a considerable treatment burden on patients, caregivers, and the health care system. Achieving sustained efficacy with fewer injections has been a major focus of research into new therapeutic options for nAMD.